CATALYST PHARMACEUTICALS, INC. 4

Insider David S. Tierney disposed of 383,314 common shares and all outstanding options and RSUs of Catalyst Pharmaceuticals, Inc. for cash at the $31.50 per‑share merger price in connection with the Angelini Pharma acquisition.

On July 15, 2026, David S. Tierney, an insider of Catalyst Pharmaceuticals, Inc., had all of his equity interests in the company—comprising 383,314 shares of common stock, multiple tranches of vested stock options, and several restricted stock unit (RSU) awards—automatically cancelled and cashed out at the $31.50 per‑share merger price in connection with the acquisition of Catalyst by Angelini Pharma S.p.A. The Form 4 reports a disposition of 383,314 common shares at $31.50 per share (aggregate value of roughly $12.1 million) and the cancellation of seven option grants (totaling 169,387 option shares across strike prices ranging from $3.42 to $22.77) and three RSU grants (totaling 8,776 units), each converted into a right to receive a cash payment based on the spread to the $31.50 merger consideration. All options were fully vested and all options and RSUs vested in full at closing, and following the merger‑related cash‑out Mr. Tierney no longer held Catalyst equity, with his post‑transaction beneficial ownership reported as zero.

Filing Facts

CIK

1369568

Ticker

CPRX

Form

4

Source Type

fda

Accession

0001161697-26-000184

Alert Tier

7